Aug 2026· International Immunopharmacology· Vol 188, pp.
117326
· 0 citations· 49 references
Medicine
TL;DR
GA alleviated LF by modulating PI3K/AKT/NF-κB signaling to inhibit M1 macrophage polarization and the pathogenic macrophage-HSC interaction, highlighting its potential as an immunomodulatory therapeutic candidate for LF.
Abstract
Liver fibrosis (LF) is a progressive pathological process driven by chronic hepatocyte injury and aberrant wound healing, culminating in excessive extracellular matrix (ECM) deposition primarily mediated by activated hepatic stellate cells (HSCs). A dysregulated hepatic immune microenvironment, orchestrated in large part by macrophages, plays a critical role in driving HSCs activation. Ginkgolide A (GA), a bioactive diterpenoid lactone from Ginkgo biloba leaves, possesses potent anti-inflammatory and antioxidant activities. However, its role and underlying mechanism in LF, particularly via modulation of macrophage-HSC crosstalk, remain unclear. In this study, we demonstrate that GA inhibited LPS-induced M1 macrophage polarization and TGF-β1-induced HSCs activation. In vivo, GA exerted potent antifibrotic effects in both NASH-associated and CCl4-induced liver fibrosis. Network pharmacology analysis identified the PI3K/AKT/NF-κB signaling pathway as a key pathway targeted by GA in LF, and molecular docking and dynamics simulations further supported the interaction between GA and PI3K. Mechanistically, GA inhibited PI3K/AKT/NF-κB signaling, and rescue experiments using a PI3K activator confirmed that this pathway is functionally required for GA-mediated suppression of M1 macrophage polarization. Collectively, GA alleviated LF by modulating PI3K/AKT/NF-κB signaling to inhibit M1 macrophage polarization and the pathogenic macrophage-HSC interaction, highlighting its potential as an immunomodulatory therapeutic candidate for LF.
It is demonstrated for the first time that Farrerol alleviates HIRI by downregulating macrophage CD14 expression, thereby inhibiting the downstream MyD88/NF-κB pathway and its associated inflammatory cascade, positioning FA as a promising therapeutic candidate and highlighting CD14 as a viable target for HIRI intervent...
Hong-Liang Liang, Jian-Sen Lu, Hao Pan et al.· International Immunopharmaco...· 0 citations
INTRODUCTION
Liver fibrosis, a key pathological step preceding cirrhosis, is characterized by the abnormal accumulation of extracellular matrix (ECM) components, a process largely driven by hepatic stellate cell activation and persistent chronic inflammation. Chlorogenic acid (CGA), a natural polyphenolic compound, has...
Yong-Qing Zhang, Lin Feng, T. Tang et al.· Current Medicinal Chemistry· 0 citations
Aberrantly activated macrophages drive acute lung injury (ALI), but how metabolic reprogramming fuels their dysfunction remains elusive. Here, we investigated PFKFB3, a glycolytic enzyme converting fructose-6-phosphate to fructose-2,6-bisphosphate, in ALI. PFKFB3 was upregulated both in LPS-stimulated macrophages and s...
Yao-Yao Wang, Juan Zeng, Xiang Dai et al.· Translational Research: The...· 0 citations
Hepatic fibrosis (HF) is a crucial and reversible stage, yet there is a paucity of effective clinical antifibrotic drugs. Salvianic acid A (SAA) has shown antifibrotic potential in preliminary studies; however, its molecular mechanisms and potential targets remain incompletely understood. To evaluate the therapeutic ef...
Jin-Qi Hu, Jie-Xin Zhang, Xiao-Mei Ge et al.· European Journal of Pharmaco...· 0 citations
Hepatic sinusoidal obstruction syndrome (HSOS) is a life-threatening liver microvascular disorder characterized by hepatic sinusoidal endothelial cells (HSECs) injury, for which safe and effective pharmacological treatments are currently lacking. Tangeretin (TAN), a natural polymethoxylated flavone, exhibits anti-infla...
Fu-Min Zhang, Cheng Zhu, Xing-Yu Li et al.· Phytotherapy Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.